World Cancer Research Journal WCRJ 2018; 5 (1): e1038

HPV AND URINARY BLADDER CARCINOMA: A REVIEW OF THE LITERATURE

G. VISALLI[1], A. FACCIOLÀ[2], F. D'ALEO[2], M. R. PINZONE[3], F. CONDORELLI[4], I. PICERNO[1], G. NUNNARI[2], G. F. PELLICANÒ[5], M. CECCARELLI[2], E. VENANZI RULLO[2]

[1]Department of Biomedical and Dental Sciences and MorphoFunctional Imaging, University of Messina, Messina, Italy
[2]Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, Messina, Italy
[3]Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
[4]Department of Pharmacological Sciences, Università del Piemonte Orientale "A. Avogadro", Novara, Italy
[5]Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy

Abstract – *Human Papillomavirus (HPV) is considered to be the second cause of virus-related cancer, as it is associated to the 30% of infection-related cancer cases. Many studies showed that HPV detection in the urinary tract depends on the sample considered. HPV infection in men is often detected in the glans, corona, prepuce, shaft of the penis, and distal urethra.*

Oncoproteins E6 and E7 play an essential role in the onset of HPV-related cancers, even if their expression is not sufficient to transform the host cell.

Two possible hypotheses are considered in the association HPV-BCs. The first involves an anatomical reason. The second hypothesis considers the natural epithelial tropism of HPV. Current evidence in literature fails to show strong associations between HPVs and these cancers.

The aim of this review was to identify key data and factors about the potential role of HPV in the genesis of BCs.

KEYWORDS: *Papillomavirus, HPV, Bladder cancer, Urinary bladder cancer, Urinary tract cancer*

INTRODUCTION

Viruses are responsible for up to 10-15% of all human cancers[1-5]. The American Association for Cancer Research (AACR) established in 2017 that infectious pathogens are the third cause of cancer worldwide. Human Papillomavirus (HPV) is considered to be the second cause of virus-related cancer, as it is associated to the 30% of infection-related cancer cases. It is preceded by *Helicobacter pylori* (32.5%) and closely followed by HBV/HCV (29.5%)[3]. Infectious agents-related cancers are of particular interest for a number of reasons. First of all, they allow to determine cellular and genetic mechanisms involved in cancer development. Secondly, but maybe more importantly, it could be possible to use selected screening programs, monitoring and vaccination to fight them[6-10].

HPVs are a group of DNA-viruses that cause one of the most common sexually transmitted infections worldwide[11]. The infection is generally asymptomatic, self-limiting, and the virus is normally cleared by the host's immune system[12]. HPV serotypes are divided in low-risk HPVs (lr-HPVs), and high-risk HPVs (hr-HPVs). This second group is involved in carcinogenesis[13].

Corresponding Author: Emmanuele Venanzi Rullo, MD; e-mail: evenanzirullo@gmail.com

Many epidemiological studies showed that healthy men, who are usually considered only a reservoir, have a higher prevalence of the HPV infection than healthy women[14-16].

A persistent HPV infection has been historically identified as the first cause of cervical cancer. Furthermore, recent studies showed that hr-HPVs have a role in the development of cancers of other districts[17,18]. A significant association has been demonstrated for anal-genital and oropharyngeal cancers, while there is a debate whether the virus might play a role in the development of urinary bladder cancers (BC)[19-26]. The aim of this review was to identify key data and factors about the potential role of HPV in the genesis of BCs.

DETECTION OF HPV IN URINARY TRACT SAMPLES

Many studies showed that HPV detection in the urinary tract depends on the sample considered. HPV infection in men is often detected in the glans, corona, prepuce, shaft of the penis, and distal urethra[15,27]. However, some previous studies using urine samples were not able to detect HPV infection in the urinary tract.

Many authors reported that urine samples are not a good sample for HPV detection (0.8-7%), while rubbing the urethral-coronal sulcus, the inner prepuce, the distal urethra, the glans, the external prepuce and the scrotum led to a 10-44% detection, depending on the source[22,27-29].

However, more recent studies showed how using polymerase chain reaction (PCR)-based methods the HPV detection improved even in urine samples[16,30-35]. These studies show that HPV can infect many sites of the urinary tract, especially urethra, prostate and urinary bladder.

A study by Kawaguchi et al[30] highlighted that liquid-based cytology can lead to a 21% detection of HPV-DNA in urine samples in patients affected by urethritis, a prevalence seven times higher than that found in healthy patients. Moreover, findings by Piyathilake et al[36] showed a substantial to almost perfect agreement in the detection of any HPV genotype in urine compared to cervical specimens regardless of population characteristics. Therefore, testing urine for HPV-DNA could become, in the future, even a replacement for the classical and annoying procedure which is the Pap-test. In addition, there is evidence suggesting that HPV infection would start on the distal urethra following a sexual contact and, from this site, it would ascend through into the bladder urothelial epithelium[37-40]. Further studies about sampling and testing techniques are needed to understand the utility of detecting HPV-DNA in urines.

ROLE OF DNA DAMAGE AND CHRONIC INFLAMMATION IN HPV-CARCINOGENESIS

HPV-induced carcinogenesis is a complex process following the infection. However, not every infection ends as cancer. Integration of viral DNA into the host genome, inflammation and high levels of inflammatory mediators have been reported in cervical neoplastic lesions as well in other cancers[41-45]. The inflammatory process promotes the integration of HPV-DNA and, consequently, the cancer progression, causing genomic instability and increased susceptibility to DNA damage[46]. Oncoproteins E6 and E7 play an essential role in the onset of HPV-related cancers, even if their expression is not sufficient to transform the host cell. As a matter of fact, genomic instability is necessary to acquire the malignant phenotype. E6 and E7 inactivate and/or degrade respectively p53 and pRb suppressor gene-associated proteins. Molecular studies suggest that the HPV related oncoproteins E6 and E7 would play a role also in bladder carcinogenesis via the same mechanisms[47,48].

Several studies showed that the increase in reactive oxygen species (ROS) and reactive nitrogen species (RNS) happening during inflammation, leading to oxidative and nitrative stress, is responsible for the rupture of cell double-stranded DNA[49-52]. This kind of damage is necessary for hr-HPV integration[53]. Moreover, ROS are able to induce the formation of oxidative DNA mutagenic products, promoting carcinogenesis especially during viral infections[49,50,54-58].

Therefore, chronic inflammation (Figure 1) can increase DNA mutations through ROS/RNS production and can promote proliferation. Other works about the association of cancer stem cells with infection and inflammation also support this idea[50,59].

However, more studies are needed to determine if this model can be applied to bladder neoplasms as well.

HPV PREVALENCE IN BLADDER CARCINOMA

BC accounts for about 3.2-4% of all cancers worldwide, and it is considerably more frequent in males than in females. Three histological types of cancers represent almost the whole amount of the urinary bladder cancers: urothelial carcinoma (UC), squamous cell carcinoma (SCC) and adenocarcinoma (AD) (Figure 2). UC is the histological type most frequently diagnosed, representing more than 90% of all cancers identified on this site[60]. Much lower frequency are SCC and AD[61]. In the past three decades, there was an increasing incidence of bladder carcinoma and this aspect has increased interest for identification of possible etiological agents. Several



Fig. 1. Role of chronic inflammation in HPV-carcinogenesis.

risk factors have been considered in the development of this cancer type, including smoking, certain industrial exposure, arsenic in drinking water, chronic irritation as well as bacterial and viral infection[62,63].

Although UC of the bladder often showed focal squamous differentiation, is different from SCC, which contains solely keratin-forming carcinoma cells. BCs composed of mixed urothelial and squamous phenotypes are known as UC with squamous



Fig. 2. Histological types of bladder cancer.

differentiation (UC/SCC)[64]. UC and SCC represent the histologic subtypes most commonly associated with HPV-induced cancer.

Several studies evaluated the potential causative role of HPV infection in BC[65-68], but the real impact in this field is still highly controversial[20,22]. Even in the most up to date studies, there is no agreement about the role of HPV in BC, with an extremely wide percentage of positive cases ranging from 0 to 80%[20]. Some studies suggested that HPV is the most important risk factor for development of carcinoma in urogenital system[16,47,69]. Moreover, other studies found an association between HPV and SCC of the urinary bladder ranging from 0% to 17%[70,71].

Two possible hypotheses are considered in the association HPV-BCs. The first involves an anatomical reason. The urethra represents a reservoir for the virus and because it directly connects urinary bladder with genital area, it can represent a natural way for viral migration. The second hypothesis considers the natural epithelial tropism of HPV. In fact, these viruses infect epithelial cells with a high tissue tropism and affinity for squamous epithelium[72]. This affinity could well explain the probable association between HPV and BCs. However, because most BCs are not SCC but UCs, this association may be weak in the majority of BCs patients.

Current evidence in literature fails to show strong associations between HPVs and these cancers. The reduced size of the studies is probably the main reason why this association cannot be demonstrated, but the rarity of this entity makes virtually impossible to conduct larger studies.

In the following sections, we reviewed the studies offering evidence in favour or against the association between HPV infection and the three principal histological forms of BCs.

Urothelial carcinoma

The first study that showed a HPV prevalence rate of 10% in UC/AD was published in 1988[73]. Since then, several studies have detected HPV in at least a subset of the analysed cases with results of HPV prevalence that varied dramatically.

Of 70 studies considered in this review, 50 showed a HPV detection in BCs, and a cause-effect association was found in 20 studies.

Studies that showed an association HPV-UC

Several investigations assigned to HPV a role in the genesis of UCs (Table 1)[19-21,23,26,47,71,73-114]. Khaled et al[95] in 2001 studied the presence of HPV serotypes 16/18 in 50 BCs using the technic of "*in situ* hybridization" with a HPV-detection on 46% of cases (23/50). Positivity was 47.8% for SCCs and 36.4% for UCs. Moreover, the authors state that HPV could be implicated also in the etiology of bilharzial bladder cancer (BBC). To this latter aim, the same author in 2003, considering 99 cases of BBCs, detected HPV-DNA in 49% of them, the majority of which (64.6%) belonging to serotype 16. These results suggest an etiological role of HPV in this type of neoplasm. Moreover, this study showed a positive trend in the correlation between tumour grade/stage and hr-HPV infection[99].

In a 2007 study, 166 bladder wash samples were obtained from 107 patients. The prevalence of all-types and hr-HPVs infection in bladder cancers was 15.2% and 8.1%, respectively. Concerning the grading, in grade 1, 2 and 3 cancers, the infection rate of hr-HPV types was 0%, 3.3%, and 10.6%, respectively (trend test: p=0.221). Finally, in Ta, T1, and T2-T4 tumours, the hr-HPVs infection rate was 0%, 12.5% and 18.2%, respectively[101].

Shigehara et al[102] in 2011, evaluated HPV-DNA in 117 cases of BCs founding the virus in 18 of them (15%). In this study, 15 (83%) of the HPV-positive cancers showed a non-invasive growth pattern and most of them had been classified as low-grade.

In 2012 Barghi et al[106] carried out a cross-sectional study in 82 male patients with BCs and their wives. Bladder tissue specimens of patients with UCs were analysed for HPV infection using a PCR method for subtypes 16 and 18. The results showed that 24 (29.3%) BC samples were positive for HPV infection. Of these, it was found HPV-18 in 9 (37.5%) and HPV-16 in 3 (12.5%). In the wives of those men, 4 (4.9%) cases showed cellular dysplasia on their Pap-tests. In those women whose husbands had BCs but no HPV infection, the authors found no case of dysplasia.

In a study carried out by Kim et al[71] the detection rate of HPV-DNA was 2-fold higher in a group of 35 patients with mixed UC/SCC of the bladder (17.5%) than the control group of 12 patients with squamous metaplasia of the bladder (8.3%). However, due to the small sample size, it is not possible establish a real statistically significant increase in risk of HPV infection in the study group. These findings agree with other investigations in which HPV-DNA was detected in both UCs and SCCs of the bladder[20].

Shigehara et al[107] in a 2013 study provided an important evidence that HPVs play an etiological role in UC of the bladder. This work involved 84 female patients with primary BCs. After DNA extraction from paraffin-embedded tissue samples, HPV-DNA and relative genotype were checked. The results showed that HPV-DNA was detected in 5 (6.0%) of 84 patients. Concerning the genotypes, HPV16 was detected in 3 patients, HPV6 and HPV52 were detected in one case, respectively. HPV-DNA detection was more frequent in younger patients and in patients with a past cervical cancer. In four hr-HPV-positive cases, hr-HPV-DNA was present in cancer tissues. Two cases had a history of

TABLE 1. Study that showed an association HPV-Bladder Cancer (UC, SCC, AD).

Year	Author	Pathology	N	HPV detection (%)	Detected HPV types (number)
1988	Kitamura	UC/AD	10	1 (10%)	16 (1)
1991	Bryant	UC/AD	100	12 (12%)	16/18 (12)
1991	Kerley	UC/SCC/AD	27	1 (3.7%)	11 (1)
1992	Chetsanga	UC	44	1 (2.3%)	16 (1)
1992	Shibutani	UC	20	4 (20%)	6/11 (2), 16/18 (1), 31/33 (1)
1992	Anwar	UC/SCC	48	39 (81%)	18 (18), 33 (14), 16 (13)
1993	Yu ST	UC	53	30 (57%)	16 (28), 18 (2)
1993	Wilczynsky	SCC	22	1 (4.5%)	6 (1)
1993	Furihata	UC	90	28 (31%)	—
1994	Mincione	UC	18	1 (5.6%)	31/33/51 (1)
1994	Agliano	UC	46	23 (50%)	16 (11), 18 (7), 16/18 (7)
1994	Maloney	UC/SCC	42	1 (4.4%)	18 (1)
1994	Noel	UC	75	2 (2.7%)	16 (2)
1995	Kamel	UC/SCC	47	27 (57%)	31 (19), 18 (16), 33 (13) 16 (10), 11 (10), 6 (13)
1995	Kim	UC	23	8 (35%)	16 (4), 18 (8)
1995	Smetana	UC	110	59 (54%)	—
1995	LaRue	UC	71	28 (39%)	16 (27), 6/11 (1)
1995	Lopez-Beltran	UC	76	7 (9.2%)	16 (7)
1995	Gopalkrishna	UC	10	1 (10%)	16 (1)
1996	Tenti	UC	79	26 (33%)	16 (21), 18 (8)
1996	Lopez-Beltran	UC	76	7 (9.2%)	16 (7), 6 (1)
1996	Mvula	UC/SCC	36	1 (2.8%)	16 (1)
1997	Chan	UC	20	6 (30%)	18 (6)
1998	Gazzaniga	UC	35	11 (31%)	16 (6), 18 (5)
1999	De Gaetani	UC	43	17 (40%)	6/11 (3), 16/18 (6), 31/33/35 (10)
1999	Simoneau	UC	187	16 (8.5%)	16 (6), 6 (3), 11 (3)
1999	Tekin	UC	42	2 (4.8%)	16 (2)
2001	Khaled	UC/SCC/AD	50	23 (46%)	16/18 (23)
2001	Sur	UC	91	1 (1.5%)	—
2003	Fioriti	UC	32	1 (3%)	6 (1)
2003	Khaled	UC/SCC	99	48 (49%)	16 (36), 18 (14), 6 (3), 11 (3)
2005	Barghi	UC	59	21 (36%)	18 (17), 6 (4), 33 (3)
2006	Helal	UC/SCC	114	1 (0.9%)	16 (1)
2007	Moonen	UC	107	15 (15%)	18 (3), 16 (2), 6 (1), 11 (1) 31 (1), 40 (1), 52 (1), UK (1)
2008	Badawi	UC/SCC	20	9 (45%)	16 (9), 18 (2)
2011	Shigehara	UC/SCC/AD	117	18 (15%)	16 (6), 18 (4), 33 (3), 31 (1) 52 (1), 56 (1), 58(1), UK (1)
2011	Cai	UC	78	27 (35%)	16 (4), 18 (6), 31 (3), 45 (5)
2011	Shigehara	AD	6	1 (16.6%)	
2012	Polesel	UC	114	7 (6.1%)	56 (2), 31 (1), 35 (1), 45 (1) 58 (1), 70 (1)
2012	Barghi	UC	82	24 (29%)	18 (9), 16 (3), UK (12)
2013	Berrada	UC/SCC	43	22 (52%)	18 (21), 31 (1)
2013	Shigehara	UC	84	5 (6%)	16 (3), 6 (1), 52 (1)
2013	Shaker	15 SQCC 45 UC		SQCC 33.3% UC 76.6% SQCC 44.4%, UC 91.6%	16/18 6/11
2013	Chapman	SCC	14	3 (21.4%)	16 (2), 35 (1)
2014	Kim	UC	35	6 (17%)	18 (6)
2016	Golovina	UC	101	38 (37.6)	16
2016	Guma	SCC	1	1 (100%)	6/11
2017	Jørgensen	SCC	1	1 (100%)	52, 66, 44, 67
2017	Abdollahzadeh	UC	67	15 (22.4%)	-

HPV, human papillomavirus; UC, urothelial carcinoma; AD, adenocarcinoma; SCC, squamous cell carcinoma; SQCC, schistosomal squamous cell carcinoma; UK, unknown.

TABLE 2. Study that refuse the association HPV-Bladder Cancer (UC, SCC, AD).

Year	Author	Pathology	N	HPV detection (%)	Detected HPV types (number)
1992	Knowles	UC/SCC/AD	108	0 (0%)	None
1993	Sinclair	UC	14	0 (0%)	None
1993	Saltzstein	UC	33	0 (0%)	None
1994	Chang	UC	108	0 (0%)	None
1995	Sano	BT	93	0 (0%)	None
1996	Boucher	UC/SCC	55	0 (0%)	None
1997	Lu	UC/SCC/AD	31	0 (0%)	None
1997	Cooper	SCC	25	0 (0%)	None
1998	Aynaud	UC	57	0 (0%)	None
2001	Westenend	SCC	16	0 (0%)	None
2005	Youshya	UC	78	0 (0%)	None
2009	Guo	SCC	16	0 (0%)	None
2010	Ben Selma	UC/SCC/AD	125	0 (0%)	None
2011	Yavuzer	UC	70	0 (0%)	None
2012	Polesel	UC	114	0 (0%)	None
2012	Blochin	SCC	2	0 (0%)	None
2012	Alexander	SCC	42	0 (0%)	None
2013	Steinestel	CIS	45	0 (0%)	None
2014	Alexander	AD	36	0 (0%)	None
2015	Schmid	BC	109	0 (0%)	None

HPV, human papillomavirus; UC, urothelial carcinoma; AD, adenocarcinoma; SCC, squamous cell carcinoma; UK, unknown.

cervical cancer with the same HPV type (HPV16) detected both from BC and cervical cancer[108].

Golovina et al[111] in 2016 collected UC tissue samples from 101 patients. Morphological analysis and HPV biomolecular detection were conducted in the cancer specimens. HPV16-DNA was detected in 38 specimens, while mRNA of E6 and E7 oncogenes and E7 oncoprotein of HPV16 were found in 13 specimens. In HPV-positive samples, it was found an association between HPV detection and a higher degree of cell anaplasia than HPV-negative cancers. Moreover, HPV was detected in primary BCs more often than in recurrent those. These data showed a sure involvement of HPV16 in the genesis of BC. No correlations were found between HPV status of BCs and patient's sex, age, and invasion into the muscle layer, which were revealed.

In a 2017 study carried out by Abdollahzadeh et al[114] in 97 biopsy specimens, including 67 patients with UCs and 30 controls, the authors identified HPV-DNA in 22.4% of patients with cancers and 3.3% of controls were positive for HPV. The HPV prevalence was 4.3-fold higher in men than women. Most UC patients belonged to grades II and III.

Study that refuses the association HPV-UC

In contrast with the above-described studies, a number of investigations did detect no presence of HPV in the evaluated cases (Table 2[67,70,105,115-131]). Many of these investigations have included a large patient subset as well. For example, Youshya et al[67] considered 78 cases of UCs but any HPV detection was observed. Likewise, Ben Selma et al[125] investigated a group of 125 BC cases, of which 119 were UCs, but the authors found no evidence of HPV detection in any case. Yavuzer et al[126] in 2011 carried out a study involving 70 UC tissues that were screened by nested-PCR for HPV-DNA with a control group of 18 cervical tissues with invasive cervical carcinoma and Cervical Intraepithelial Neoplasia III (CIN III). In the study group, the authors did not find HPV-DNA positivity in any of the considered UCs.

In 2012, a study of Polesel et al[105] considering 114 UC cases, screened urine samples to detect DNA of 22 mucosal HPVs using highly sensitive PCR assays. HPVs were detected only in seven cases and five controls (OR=1.52; 95% CI: 0.42-5.45). The study does not suggest an involvement of HPVs infection in UC aetiology in immunocompetent individuals.

Steinestel et al[129] in 2013 collected 60 specimens of urothelial carcinoma *in situ* (UCIS) from 45 patients, and a control group with CIN. In the specimens, the authors performed p16(INK4a) immunohistochemistry followed by detection and subclassification of HPV-DNA. The results showed the presence of hr-HPV-DNA in 80% of CIN, but none in UCIS.

Finally, Schmid et al[131] in 2015 conducted a study involving 109 cases of BC with 41 superficial (pTa low grade) cancers, 56 invasive (pT1-T4) high grade cancers and 12 other types (pTa high grade + pTis). The authors did not detect HPV-DNA in any sample (95% Confidence Interval (CI) 0-3.3%). The results suggest that it is improbable that HPV infections can play an important role in the development of UC.

Squamous Cell Carcinoma (SCC)

The literature concerning the hypothetical role of HPV in SCC pathogenesis is poor and provides conflicting results. Some investigations have identified a link between HPV and this kind of cancer, while other studies have reported no association between HPVs and SCC pathogenesis (Table 1 and 2).

Study that showed an association HPV-SCC

Chapman-Fredricks et al[110] enrolled 14 cases of primary bladder SCC, positive for p16 by immunohistochemistry, to detect hr-HPV by *in situ* hybridization and the signal amplification Invader assay. The results showed that the hr-HPV detection by the *in-situ* hybridization method was negative in all cases. However, in 3 of 14 cases (21.4%), the presence of hr-HPV-DNA was detected with the Cervista hr-HPV Invader assay, with the subsequent identification of genotype. hr-HPV type specific amplification followed by DNA sequencing confirmed all positive cases. Identified genotypes were HPV 16 in 2 cases and HPV 35 in 1 case. This study concluded that hr-HPV-DNA is detectable in a subset of primary bladder SCCs.

At the same time in 2013 Shaker et al[109] investigated the HPV role on 60 bladder specimens, of which 15 were schistosomal squamous cell carcinoma (SQCC) and 45 were schistosomal and non-schistosomal UCs. The results showed that HPV 16/18 were found in 33.3%, 50% and 26.6%, respectively, while the positivity to HPV 6/11 were 44.4%, 58.3% and 33.3% for SQCCs, UCs and UC/SCC, respectively. Seven cases of UCs had both HPV6/11 and 16/18.

A study carried out in 2016 by Guma et al[112] demonstrates that the infection with HPV 6/11 was associated with an UC with squamous differentiation and condylomatous features. This is a case report on a high-grade UC with focal areas of squamous differentiation. These areas showed koilocytic differentiation, which was positive for strong p16 expression. In this cancer, it was found positivity for lr-HPV 6/11 by *in situ* hybridization technic.

Jorgensen et al[113] reported in a case of bladder SCC the presence of four different HPV types: hr-HPV-52, hr-HPV-66p, lr-HPV-44 and HPV-67. However, the association between the risk to develop SCC in the urinary bladder and the multiple infection with different HPV genotypes as seen in this patient is still unknown.

Study that refuses the association HPV-SCC

Westenend et al[70] in 2001 and Guo et al[124] in 2009 carried out two small investigations involving both 16 cases of SCC of the urinary bladder. In both studies no cases of HPV were detected.

A larger and more recent study conducted by Alexander et al[128] did not find evidence of HPV presence in 42 SCC cases. Moreover, the same authors performed the analysis on 27 cases of UCs with squamous differentiation, a morphologically similar entity to SCC of the urinary bladder. Even in this case, the results showed no evidence of HPV. These studies agree with the findings reported on UC with squamous differentiation from Blochin et al[127] in 2012. Other previous studies also failed to find HPV infection in bladder SCC cases. In conclusion, the role of detecting HPVs in the urinary bladder SCC is uncertain. HPV infection could have a little or no influence in the development of SCC of the bladder, but there is necessity of further researches to clarify this association.

Adenocarcinoma of urinary bladder (AD)

Even in case of AD of urinary bladder, the literature is quite poor and conflicting (Table 1 and 2). A study carried out by Alexander et al[130] on 36 cases of clinically confirmed cases of primary AD of the urinary bladder has not detected HPV in any of the examined cases. Conversely, a large study on BCs conducted by Shigehara et al[104] evaluated six AD of urinary bladder cases founding HPV-DNA in one case using PCR method; however, the extremely small number of considered specimens, do not allow any significant conclusions.

CONCLUSIONS

In the past three decades, the incidence of bladder carcinoma increased worldwide inducing the authors to identify possible etiological agents. Among the well-known cancer causes (smoking, industrial exposure, heavy metals in drinking water, chronic irritation) an increasing interest there was about a possible role played by HPVs in the pathogenesis of this kind of cancers. A thirty years' literature was not able to clearly demonstrate the real contribute of HPV in this oncologic disease. The difference among the studies is probably due to sampling problems, contamination, sensitivity of the detection systems, geographic variation and size of the studies, especially regarding the rarer forms[129]. Further studies are required to understand and clarify the role of HPV in the pathogenesis of this kind of urinary cancers.

Conflict of Interest:
The Authors declare that they have no conflict of interests.

REFERENCES

1. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 2010; 10: 878-889.
2. Facciolà A, Venanzi Rullo E, Ceccarelli M, D'Aleo F, Di Rosa M, Pinzone MR, Condorelli F, Visalli G, Picerno I, Fisichella R, Nunnari G, Pellicanò GF. Kaposi's sarcoma in HIV-infected patients in the era of new antiretrovirals. Eur Rev Med Pharmacol Sci 2017; 21: 5868-5869.
3. American Association for Cancer Research (AACR). Cancer Progress Report 2017. http://www.cancerprogressreport.org/Pages/cpr17-preventing-cancer.aspx.
4. La Ferla L, Pinzone MR, Pellicanò GF, Nunnari G. Kaposi's sarcoma in HIV-infected patients: a review of the literature. Infect Dis Trop Med 2016; 2: e239.
5. Colafigli M, Bonadies A, Ferraresi V, Tonachella R, Cristaudo A, Latini A. Kaposi sarcoma in HIV-infected patients: an infectious-dermatological outpatient service experience. Infect Dis Trop Med 2017; 3: e410.
6. D'Aleo F, Ceccarelli M, Venanzi Rullo E, Facciolà A, Di Rosa M, Pinzone MR, Condorelli F, Visalli G, Picerno I, Berretta M, Pellicanò GF, Nunnari G. Hepatitis C-related hepatocellular carcinoma: diagnostic and therapeutic management in HIV-patients. Eur Rev Med Pharmacol Sci 2017; 21: 5859-5867.
7. Alexander RE, Wang L, Lopez-Beltran A, Emerson RE, Montironi R, Pedrosa JA, Kaimakliotis HZ, Koch MO, Cheng L. Human papillomavirus (HPV)-induced neoplasia in the urinary bladder: a missing link? Histol Histopathol 2016; 31: 595-600.
8. Stanley M. Tumour virus vaccines: hepatitis B virus and human papillomavirus. Philos Trans R Soc Lond B Biol Sci 2017; 372. doi: 10.1098/rstb.2016.0268
9. Cenderello G, Tittle V, Pasa A, Dentone C, Artioli S, Barbour A, Setti M, Giacomini M, Fraccaro P, Viscoli C, Cassola G, Nelson M, Di Biagio A. The impact of liver disease: a leading cause of hospital admissions in people living with HIV. Infect Dis Trop Med 2015; 1: e167.
10. Rizzo L, Pinzone MR, L'Abbate L, Attanasio M, Nunnari G, Cacopardo B. Quantitative ARFI elastography predicts short-term decompensation in HCV-related cirrhosis. Infect Dis Trop Med 2016; 2: e345.
11. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350.
12. Tolstov Y, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S. Human papillomaviruses in urological malignancies: a critical assessment. Urol Oncol 2014; 32: 46.e19-e27.
13. Visalli G, Currò M, Facciolà A, Riso R, Mondello P, Laganà P, Di Pietro A, Picerno I, Spataro P. Prevalence of human papillomavirus in saliva of women with HPV genital lesions. Infect Agent Cancer 2016; 11: 48.
14. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-1799.
15. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006; 194: 1044-1057.
16. Shigehara K, Sasagawa T, Kawaguchi S, Kobori Y, Nakashima T, Shimamura M, Taya T, Furubayashi K, Namiki M. Prevalence of human papillomavirus infection in the urinary tract in men with urethritis. Int J Urol 2010; 17: 563-568.
17. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 14: 24-35.
18. Ouhoummane N, Steben M, Coutlée F, Vuong T, Forest P, Rodier C, Louchini R, Duarte E, Brassard P. Squamous anal cancer: patient characteristics and HPV type distribution. Cancer Epidemiol 2013; 37: 807-812.
19. Bryant P, Davies P, Wilson D. Detection of human papillomavirus DNA in cancer of the urinary bladder by in situ hybridisation. Br J Urol 1991; 68: 49-52.
20. Anwar K, Naiki H, Nakakuki K, Inuzuka M. High frequency of human papillomavirus infection in carcinoma of the urinary bladder. Cancer 1992; 70: 1967-1973.
21. Lopez-Beltran A, Escudero AL, Carrasco-Aznar JC, Vicioso-Recio L. Human papillomavirus infection and transitional cell carcinoma of the bladder. Immunohistochemistry and in situ hybridization. Pathol Res Pract 1996; 192: 154e9.
22. Lopez-Beltran A, Escudero AL. Human papillomavirus and bladder cancer. Biomed Pharmacother 1997; 51: 252-257.
23. Tekin MI, Tuncer S, Aki FT, Bilen CY, Aygün C, Ozen H. Human papillomavirus associated with bladder carcinoma? Analysis by polymerase chain reaction. Int J Urol 1999; 6: 184-186.
24. Weiss RA. On viruses, discovery, and recognition. Cell 2008; 135: 983-986.
25. Cobos C, Figueroa JA, Mirandola L, Colombo M, Summers G, Figueroa A, Aulakh A, Konala V, Verma R, Riaz J, Wade R, Saadeh C, Rahman RL, Pandey A, Radhi S, Nguyen DD, Jenkins M, Chiriva-Internati M, Cobos E. The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review. Int Rev Immunol 2014; 33: 383-401.
26. Yu ST, Wu MM, Li LM. Prevalence of human papillomaviruses 16 and 18 in transitional cell carcinoma of bladder. Chin Med J 1993; 106: 494-496.
27. Giuliano AR, Nielson CM, Flores R, Dunne EF, Abrahamsen M, Papenfuss MR, Markowitz LE, Smith D, Harris RB. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. J Infect Dis 2007; 196: 1146-1152.
28. Lazcano-Ponce E, Herrero R, Munoz N, Hernandez-Avila M, Salmeron J, Leyva A, Meijer CJ, Walboomers JM. High prevalence of human papillomavirus infection in Mexican males: comparative study of penile-urethral swabs and urine samples. Sex Transm Dis 2001; 28: 277-280.
29. Nicolau SM, Camargo CG, Stávale JN, Castelo A, Dôres GB, Lörincz A, de Lima GR. Human papillomavirus DNA detection in male sexual partners of women with genital human papillomavirus infection. Urology 2005; 65: 251-255.
30. Kawaguchi S, Shigehara K, Sasagawa T, Shimamura M, Nakashima T, Sugimoto K, Nakashima K, Furubayashi K, Namiki M. Liquid-based urine cytology as a tool for detection of human papillomavirus, Mycoplasma spp., and Ureaplasma spp. in men. J Clin Microbiol 2012; 50: 401-406.
31. Shigehara K, Sasagawa T, Namiki M. Human papillomavirus infection and pathogenesis in urothelial cells: a mini-review. J Infect Chemother 2014; 20: 741-747.

32. Nakashima K, Shigehara K, Kawaguchi S, Wakatsuki A, Kobori Y, Nakashima K, Ishii Y, Shimamura M, Sasagawa T, Kitagawa Y, Mizokami A, Namiki M. Prevalence of human papillomavirus infection in the oropharynx and urine among sexually active men: a comparative study of infection by papillomavirus and other organisms, including Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma spp., and Ureaplasma spp. BMC Infect Dis 2014; 14: 43.
33. Leeman A, Del Pino M, Molijn A, Rodriguez A, Torné A, de Koning M, Ordi J, van Kemenade F, Jenkins D, Quint W. HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population. BJOG 2017; 124: 1356-1363.
34. Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. Br Med J 2014; 349: g5264.
35. Edelstein ZR, Schwartz SM, Hawes S, Hughes JP, Feng Q, Stern ME, O'Reilly S, Lee SK, Fu Xi L, Koutsky LA. Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis 2012; 39: 860-867.
36. Piyathilake CJ, Badiga S, Chambers MM, Brill IK, Matthews R, Partridge EE. Accuracy of urinary human papillomavirus testing for the presence of cervical human papillomaviruses and higher grades of cervical intraepithelial neoplasia. Cancer 2016; 122: 2836-2844.
37. Kawaguchi S, ShigeharaK, Sasagawa T, KuribayashiM, Junicho A, Hasegawa T, Maeda Y, Namiki M. A case study of human papillomavirus-associated bladder carcinoma developing after urethral condyloma acuminatum. Jpn J Clin Oncol 2012; 42: 455e8.
38. Chrisofos M, Skolarikos A, Lazaris A, Bogris S, Deliveliotis Ch. HPV 16/18-associated condyloma acuminatum of the urinary bladder: first international report and review of literature. Int J STD AIDS 2004; 15: 836-838.
39. Karim RZ, Rose BR, Brammah S, Scolyer RA. Condylomata acuminata of the urinary bladder with HPV 11. Pathology 2005; 37: 176-178.
40. Tena-Suck ML, Alarc on-Herrera A, Tirado-Sanchez A, Rösl F, Astudillo-de la Vega H. Male urethral pap smears and peniscopy examination and polymerase chain reaction human papillomavirus correlation. Diagn Cytopathol 2012; 40: 597-603.
41. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001; 7: 429-434.
42. Kim GE, Kim YB, Cho NH, Chung HC, Pyo HR, Lee JD, Park TK, Koom WS, Chun M, Suh CO. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix. Clin Cancer Res 2004; 10: 1366-1374.
43. Saldivar JS, Lopez D, Feldman RA, Tharappel-Jacob R, de la Rosa A, Terreros D, Baldwin WS. COX-2 overexpression as a biomarker of early cervical carcinogenesis: a pilot study. Gynecol Oncol 2007; 107: 155-162.
44. Koike K. Hepatitis B virus X gene is implicated in liver carcinogenesis. Cancer Lett 2009; 286: 60-68.
45. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29: 2309-2324.
46. Marullo R, Werner E, Zhang H, Chen GZ, Shin DM, Doetsch PW. HPV16 E6 and E7 proteins induce a chronic oxidative stress response via NOX2 that causes genomic instability and increased susceptibility to DNA damage in head and neck cancer cells. Carcinogenesis 2015; 36: 1397-1406.
47. Barghi MR, Hajimohammadmehdiarbab A, Moghaddam SM, Kazemi B. Correlation between human papillomavirus infection and bladder transitional cell carcinoma. BMC Infect Dis 2005; 5: 102.
48. Wolff EM, Liang G, Jones PA. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005; 2: 502-510.
49. Ma N, Thanan R, Kobayashi H, Hammam O, Wishahi M, El Leithy T, Hiraku Y, Amroe K, Oikawa S, Ohnishi S, Murata M, Kawanishi S. Nitrative DNA damage and Oct3/4 expression in urinary bladder cancer with Schistosoma haematobium infection. Biochem Biophys Res Commun 2011; 414: 344-349.
50. Thanan R, Ma N, Iijima K, Abe Y, Koike T, Shimosegawa T, Pinlaor S, Hiraku Y, Oikawa S, Murata M, Kawanishi S. Proton pump inhibitors suppress iNOS dependent DNA damage in Barrett's esophagus by increasing Mn-SOD expression. Biochem Biophys Res Commun 2012; 421: 280-285.
51. Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, Tanaka Y, Kurashige J, Miyamoto Y, Baba H. CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep 2013; 29: 1570-1578.
52. Sawicka E, Lisowska A, Kowal P, Dlugosz A. The role of oxidative stress in bladder cancer. Postepy Hig Med Dosw (Online) 2015; 69: 744-752.
53. Chen Wongworawat Y, Filippova M, Williams VM, Filippov V, Duerksen-Hughes PJ. Chronic oxidative stress increases the integration frequency of foreign DNA and human papillomavirus 16 in human keratinocytes. Am J Cancer Res 2016; 6: 764-780.
54. Kawanishi S, Hiraku Y, Oikawa S. Mechanism of guanine-specific DNA damage by oxidative stress and its role in carcinogenesis and aging. Mutat Res 2001; 488: 65-76.
55. Kawanishi S, Ohnishi S, Ma N, Hiraku Y, Oikawa S, Murata M. Nitrative and oxidative DNA damage in infection-related carcinogenesis in relation to cancer stem cells. Genes Environ 2016; 38: 26.
56. Murata M, Thanan R, Ma N, Kawanishi S. Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. J Biomed Biotechnol 2012; 2012: 623019.
57. Lai D, Tan CL, Gunaratne J, Quek LS, Nei W, Thierry F, Bellanger S. Localization of HPV-18 E2 at mitochondrial membranes induces ROS release and modulates host cell metabolism. PLoS One 2013; 8: e75625.
58. Visalli G, Riso R, Facciolà A, Mondello P, Caruso C, Picerno I, Di Pietro A, Spataro P, Bertuccio MP. Higher levels of oxidative DNA damage in cervical cells are correlated with the grade of dysplasia and HPV infection. J Med Virol 2016; 88: 336-344.
59. Hiraku Y, Kawanishi S, Ichinose T, Murata M. The role of iNOS-mediated DNA damage in infection- and asbestos-induced carcinogenesis. Ann N Y Acad Sci 2010; 1203: 15-22.
60. Van der Meijden AP. Bladder cancer. Br Med J 1998; 317: 1366-1369.
61. Silverberg E. Statistical and epidemiologic data on urologic cancer. Cancer 1987; 60: 692-717.
62. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306: 737-745.
63. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63: 234-241.

64. Grignon DJ, El-Bolkainy MN, Schmitz-Drager BJ, Simon R, Tyoznski JE. 2004. Squamous cell carcinoma; Eble JN SG, Epstein JI, Sesterhenn IA, editor. Lyon, France: IARC Press. 3p.
65. zur Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res 1989; 49: 4677-4681.
66. Wiener JS, Walther PJ. A high association of oncogenic human papillomaviruses with carcinomas of the female urethra: polymerase chain reaction-based analysis of multiple histological types. J Urol 1994; 151: 49-53.
67. Youshya S, Purdie K, Breuer J, Proby C, Sheaf MT, Oliver RT, Baithun S. Does human papillomavirus play a role in the development of bladder transitional cell carcinoma? A comparison of PCR and immunohistochemical analysis. J Clin Pathol 2005; 58: 207-210.
68. Gutierrez J, Jimenez A, de Dios Luna J, Soto MJ, Sorlozano A. Meta-analysis of studies analyzing the relationship between bladder cancer and infection by human papillomavirus. J Urol 2006; 176: 2474-2481.
69. Griffiths TR, Mellon JK. Human papillomavirus and urological tumours: II. Role in bladder, prostate, renal and testicular cancer. BJU Int 2000; 85: 211-217.
70. Westenend PJ, Stoop JA, Hendriks JG. Human papillomaviruses 6/11, 16/18 and 31/33/51 are not associated with squamous cell carcinoma of the urinary bladder. BJU Int 2001; 88: 198-201.
71. Kim SH, Joung JY, Chung J, Park WS, Lee KH, Seo HK. Detection of human papillomavirus infection and p16 immunohistochemistry expression in bladder cancer with squamous differentiation. PLoS One 2014; 9: e93525.
72. Egawa N, Egawa K, Griffin H, Doorbar J. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses 2015; 7: 3863-3890.
73. Kitamura T, Yogo Y, Ueki T, Murakami S, Aso Y. Presence of human papillomavirus type 16 genome in bladder carcinoma in situ of a patient with mild immunodeficiency. Cancer Res 1988; 48: 7207-7211.
74. Kerley SW, Persons DL, Fishback JL. Human papillomavirus and carcinoma of the urinary bladder. Mod Pathol 1991; 4: 316-319.
75. Chetsanga C, Malmstrom PU, Gyllensten U, Moreno-Lopez J, Dinter Z, Pettersson U. Low incidence of human papillomavirus type 16 DNA in bladder tumor detected by the polymerase chain reaction. Cancer 1992; 69: 1208-1211.
76. Shibutani YF, Schoenberg MP, Carpiniello VL, Malloy TR. Human papillomavirus associated with bladder cancer. Urology 1992; 40: 15-17.
77. Wilczynski SP, Oft M, Cook N, Liao SY, Iftner T. Human papillomavirus type 6 in squamous cell carcinoma of the bladder and cervix. Hum Pathol 1993; 24: 96-102.
78. Furihata M, Inoue K, Ohtsuki Y, Hashimoto H, Terao N, Fujita Y. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res 1993; 53: 4823-4827.
79. Mincione GP, Messerini L, Saltutti C, Di Cello V, Dominici A, Giannelli E, Baroni G, Calzolari A. HPV and p53 in urinary bladder carcinoma. Pathologica 1994; 86: 244-246.
80. Aglianò AM, Gradilone A, Gazzaniga P, Napolitano M, Vercillo R, Albonici L, Naso G, Manzari V, Frati L, Vecchione A. High frequency of human papillomavirus detection in urinary bladder cancer. Urol Int 1994; 53: 125e9.
81. Maloney KE, Wiener JS, Walther PJ. Oncogenic human papillomaviruses are rarely associated with squamous cell carcinoma of the bladder: evaluation by differential polymerase chain reaction. J Urol 1994; 151: 360-364.
82. Noel JC, Thiry L, Verhest A, Deschepper N, Peny MO, Sattar AA, Schulman CC, Haot J. Transitional cell carcinoma of the bladder: evaluation of the role of human papillomaviruses. Urology 1994; 44: 671-675.
83. Kamel D, Pääkkö P, Pöllänen R, Vähäkangas K, Lehto VP, Soini Y. Human papillomavirus DNA and abnormal p53 expression in carcinoma of the urinary bladder. APMIS 1995; 103:331-338.
84. Kim KH, Kim YS. Analysis of p53 tumor suppressor gene mutations and human papillomavirus infection in human bladder cancers. Yonsei Med J 1995; 36:322-331.
85. Smetana Z, Keller T, Leventon-Kriss S, Huszar M, Lindner A, Mitrani-Rosenbaum S. Presence of human papilloma virus in transitional cell carcinoma in Jewish population in Israel. Cell Mol Biol (Noisy-le-grand) 1995; 41: 1017-1023.
86. LaRue H, Simoneau M, Fradet Y. Human papillomavirus in transitional cell carcinoma of the urinary bladder. Clin Cancer Res 1995; 1:435-440.
87. Lopez-Beltran A, Munoz E. Transitional cell carcinoma of the bladder: low incidence of human papillomavirus DNA detected by the polymerase chain reaction and in situ hybridization. Histopathology 1995; 26: 565-569.
88. Gopalkrishna V, Srivastava AN, Hedau S, Sharma JK, Das BC. Detection of human papillomavirus DNA sequences in cancer of the urinary bladder by in situ hybridisation and polymerase chain reaction. Genitourin Med 1995; 71: 231-233.
89. Tenti P, Zappatore R, Romagnoli S, Civardi E, Giunta P, Scelsi R, Stella G, Carnevali L. p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: correlation with histological parameters. J Pathol 1996; 178: 65-70.
90. Mvula M, Iwasaka T, Iguchi A, Nakamura S, Masaki Z, Sugimori H. Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? J Urol 1996; 155: 471-474.
91. Chan KW, Wong KY, Srivastava G. Prevalence of six types of human papillomavirus in inverted papilloma and papillary transitional cell carcinoma of the bladder: an evaluation by polymerase chain reaction. J Clin Pathol 1997; 50: 1018-1021.
92. Gazzaniga P, Vercillo R, Gradilone A, Silvestri I, Gandini O, Napolitano M, Giuliani L, Fioravanti A, Gallucci M, Aglianò AM. Prevalence of papillomavirus, Epstein-Barr virus, cytomegalovirus, and herpes simplex virus type 2 in urinary bladder cancer. J Med Virol 1998; 55: 262-267.
93. De Gaetani C, Ferrari G, Righi E, Bettelli S, Migaldi M, Ferrari P, Trentini GP. Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridization. J Clin Pathol 1999; 52: 103-106.
94. Simoneau M, LaRue H, Fradet Y. Low frequency of human papillomavirus infection in initial papillary bladder tumors. Urol Res 1999; 27: 180-184.
95. Khaled HM, Raafat A, Mokhtar N, Zekri AR, Gaballah H. Human papilloma virus infection and overexpression of p53 protein in bilharzial bladder cancer. Tumori 2001; 87: 256-261.
96. Sur M, Cooper K, Allard U. Investigation of human papillomavirus in transitional cell carcinomas of the urinary bladder in South Africa. Pathology 2001; 33: 17-20.

97. Fioriti D, Pietropaolo V, Dal Forno S, Laurenti C, Chiarini F, Degener AM. Urothelial bladder carcinoma and viral infections: different association with human polyomaviruses and papillomaviruses. Int J Immunopathol Pharmacol 2003; 16: 283-288.
98. Khaled HM, Bahnassi AA, Zekri AR, Kassem HA, Mokhtar N. Correlation between p53 mutations and HPV in bilharzial bladder cancer. Urol Oncol 2003; 21: 334-341.
99. Helal Tel A, Fadel MT, El-Sayed NK. Human papilloma virus and p53 expression in bladder cancer in Egypt: relationship to schistosomiasis and clinicopathologic factors. Pathol Oncol Res 2006; 12: 173-178.
100. Moonen PM, Bakkers JM, Kiemeney LA, Schalken JA, Melchers WJ, Witjes JA. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 2007; 52: 464-468.
101. Badawi H, Ahmed H, Ismail A, Diab M, Moubarak M, Badawy A. Role of human papillomavirus types 16, 18, and 52 in recurrent cystitis and urinary bladder cancer among Egyptian patients. Medscape J Med 2008; 10: 232.
102. Shigehara K, Sasagawa T, Kawaguchi S, Nakashima T, Shimamura M, Maeda Y, Konaka H, Mitzokami A, Koh E, Namiki M. Etiologic role of human papillomavirus infection in bladder carcinoma. Cancer 2011; 117: 2067-2076.
103. Cai T, Mazzoli S, Meacci F, Nesi G, Geppetti P, Malossini G, Bartoletti R. Human papillomavirus and non-muscle invasive urothelial bladder cancer: potential relationship from a pilot study. Oncol Rep 2011; 25: 485-489.
104. Shigehara K, Sasagawa T, Doorbar J, Kawaguchi S, Kobori Y, Nakashima T, Shimamura M, Maeda Y, Miyagi T, Kitagawa Y, Kadono Y, Konaka H, Mizokami A, Koh E, Namiki M. Etiological role of human papillomavirus infection for inverted papilloma of the bladder. J Med Virol 2011; 83: 277-285.
105. Polesel J, Gheit T, Talamini R, Shahzad N, Lenardon O, Sylla B, La Vecchia C, Serraino D, Tommasino M, Franceschi S. Urinary human polyomavirus and papillomavirus infection and bladder cancer risk. Br J Cancer 2012; 106: 222-226.
106. Barghi MR, Rahjoo T, Borghei M, Hosseini-Moghaddam SM, Amani D, Farrokhi B. Association between the evidence of human papilloma virus infection in bladder transitional cell carcinoma in men and cervical dysplasia in their spouses. Arch Iran Med 2012; 15: 572-574.
107. Berrada N, Al-Bouzidi A, Ameur A, Abbar M, El-Mzibri M, Ameziane-El-Hassani R, Benbacer L, Khyatti M, Qmichou Z, Amzazi S, Attaleb M. Human papillomavirus detection in Moroccan patients with bladder cancer. J Infect Dev Ctries 2013; 7: 586-592.
108. Shigehara K, Kawaguchi S, Sasagawa T, Nakashima K, Nakashima T, Shimamura M, Namiki M. Etiological correlation of human papillomavirus infection in the development of female bladder tumor. APMIS 2013; 121: 1169-1176.
109. Shaker OG, Hammam OA, Wishahi MM. Is there a correlation between HPV and urinary bladder carcinoma? Biomed Pharmacother 2013; 67: 183-191.
110. Chapman-Fredricks JR, Cioffi-Lavina M, Accola MA, Rehrauer WM, Garcia-Buitrago MT, Gomez-Fernandez C, Ganjei-Azar P, Jordà M. High-risk human papillomavirus DNA detected in primary squamous cell carcinoma of urinary bladder. Arch Pathol Lab Med 2013; 137: 1088-1093.
111. Golovina DA, Ermilova VD, Zavalishina LE, Andreeva Yu Yu, Matveev VB, Frank GA, Volgareva GM. Loss of cell differentiation in HPV-associated bladder cancer. Bull Exp Biol Med 2016; 161: 96-98.
112. Guma S, Maglantay R, Lau R, Wieczorek R, Melamed J, Deng FM, Zhou M, Makarov D, Lee P, Pincus MR, Pei ZH. Papillary urothelial carcinoma with squamous differentiation in association with human papilloma virus: case report and literature review. Am J Clin Exp Urol. 2016;4:12-16.
113. Jørgensen Kit Riegels J, Høyer Søren, Møller Sørensenc Mette and Bjerggaard Jensen Jørgen. Human papillomavirus types 44, 52, 66 and 67 detected in a woman with squamous cell carcinoma of the urinary bladder. Scand J Urol 2017; 51:85-86.
114. Abdollahzadeh P, Madani SH, Khazaei S, Sajadimajd S, Izadi B, Najafi F. Association Between Human Papillomavirus and Transitional Cell Carcinoma of the Bladder. Urol J 2017; 14:5047-5050.
115. Knowles MA. Human papillomavirus sequences are not detectable by Southern blotting or general primer-mediated polymerase chain reaction in transitional cell tumours of the bladder. Urol Res 1992; 20:297-301.
116. Sinclair AL, Nouri AM, Oliver RT, Sexton C, Dalgleish AG. Bladder and prostate cancer screening for human papillomavirus by polymerase chain reaction: conflicting results using different annealing temperatures. Br J Biomed Sci 1993; 50:350-354.
117. Saltzstein DR, Orihuela E, Kocurek JN, Payne DA, Chan TS, Tyring SK. Failure of the polymerase chain reaction (PCR) to detect human papilloma virus (HPV) in transitional cell carcinoma of the bladder. Anticancer Res 1993; 13:423-425.
118. Chang F, Lipponen P, Tervahauta A, Syrjanen S, Syrjänen K. Transitional cell carcinoma of the bladder: failure to demonstrate human papillomavirus deoxyribonucleic acid by in situ hybridization and polymerase chain reaction. J Urol 1994; 152: 1429-1433.
119. Sano T, Sakurai S, Fukuda T, Nakajima T. Unsuccessful effort to detect human papillomavirus DNA in urinary bladder cancers by the polymerase chain reaction and in situ hybridization. Pathol Int 1995; 45: 506-512.
120. Boucher NR, Scholefield JH, Anderson JB. The aetiological significance of human papillomavirus in bladder cancer. Br J Urol 1996; 78: 866-869.
121. Lu QL, Lalani el-N, Abel P. Human papillomavirus 16 and 18 infection is absent in urinary bladder carcinomas. Eur Urol 1997; 31: 428-432.
122. Cooper K, Haffajee Z, Taylor L. Human papillomavirus and schistosomiasis associated bladder cancer. Mol Pathol 1997; 50: 145-148.
123. Aynaud O, Tranbaloc P, Orth G. Lack of evidence for a role of human papillomaviruses in transitional cell carcinoma of the bladder. J Urol 1998; 159: 86-89.
124. Guo CC, Gomez E, Tamboli P, Bondaruk JE, Kamat A, Bassett R, Dinney CP, Czerniak BA. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol 2009; 40: 1448-1452.
125. Ben Selma W, Ziadi S, Ben Gacem R, Amara K, Ksiaa F, Hachana M, Trimeche M. Investigation of human papillomavirus in bladder cancer in a series of Tunisian patients. Pathol Res Pract 2010; 206: 740-743.
126. Yavuzer D, Karadayi N, Salepci T, Baloglu H, Bilici A, Sakirahmet D. Role of human papillomavirus in the development of urothelial carcinoma. Med Oncol 2011; 28: 919-923.

127. Blochin EB, Park KJ, Tickoo SK, Reuter VE, Al-Ahmadie H. Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection. Mod Pathol 2012; 25: 1534-1542.
128. Alexander RE, Hu Y, Kum JB, Montironi R, Lopez-Beltran A, Maclennan GT, Idrees MT, Emerson RE, Ulbright TM, Grignon DG, Eble JN, Cheng L. p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. Mod Pathol 2012; 25: 1526-1533.
129. Steinestel J, Cronauer MV, Müller J, Al Ghazal A, Skowronek P, Arndt A, Kraft K, Schrader M, Schrader AJ, Steinestel K. Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection. PLoS One 2013; 8: e65189.
130. Alexander RE, Williamson SR, Richey J, Lopez-Beltran A, Montironi R, Davidson DD, Idrees MT, Jones CL, Zhang S, Wang L, Rao Q, Pedrosa JA, Kaimakliotis HZ, Monn MF, Koch MO, Cheng L. The expression patterns of p53 and p16 and an HPV induced urothelial neoplasia analysis of a possible role of HPV in primary adenocarcinoma of the urinary bladder. PLoS One 2014; 9: e95724.
131. Schmid SC, Thümer L, Schuster T, Horn T, Kurtz F, Slotta-Huspenina J, Seebach J, Straub M, Maurer T, Autenrieth M, Kübler H, Retz M, Protzer U, Gschwend JE, Hoffmann D. Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study. Infectious Infect Agent Cancer 2015; 10: 31.